GlobalData on MSN8d
FDA approves Roche’s Tecentriq Hybreza for cancer
The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...
FiercePharma8d
After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug
It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s ...
Zacks.com on MSN8d
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug ...
Managed Healthcare Executive8d
FDA Approves Subcutaneous Tecentriq to Treat Multiple Cancers
Tecentriq Hybreza can be administered over seven minutes, compared with 30 to 60 minutes for IV infusion of Tecentriq. There ...
Cure Today9d
FDA Approves Subcutaneous Tecentriq Formulation
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin ...
Monthly Prescribing Reference8d
FDA Approves Tecentriq Hybreza, a Subcutaneously Administered PD-L1 Inhibitor
The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...
Targeted Oncology6d
Atezolizumab After Vemurafenib and Cobimetinib Shows Trend Toward Better OS in Melanoma
Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not ...